the Study on Prognostic for Hemodialysis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03194087|
Recruitment Status : Recruiting
First Posted : June 21, 2017
Last Update Posted : June 21, 2017
|Condition or disease|
It is common that the abnormalities in parathyroid hormone (PTH) levels appear in patients with moderate and advanced chronic kidney diseases (CKD). CKD-mineral and bone disorder (CKD-MBD), manifested by the serum calcium (Ca), phosphorus (P), and parathyroid hormone (PTH) levels, and other abnormalities such as vitamin D metabolism and bone turnover etc, contribute to the increased morbidity and mortality in patients on maintenance dialysis.
Results from KDOQI guidelines, indicated that an increased mortality risk was associated with high parathyroid hormone (PTH) levels, if the PTH levels >600pg/ml, it means severe secondary hyperparathyroidism, it have been shown to contribute to alterations of arterial structure and function and associated with cardiovascular (CV), calcifications, CV events, and death.
In most patients, SHPT can be successfully controlled by dialysis and supplements of calcium and vitamin D. but Results from several studies, the severe secondary hyperparathyroidism can't be control by medical treatment or hemodialysis, about 15% of patients after 10 years and 38% of patients after 20 years of dialysis need parathyroidectomy. total parathyroidectomy(tPTX) is the best Surgical approach. tPTX seems to be associated to a lower relapse rate but higher percentage of hypoparathyroidism. But it may cause the patient in low parathyroid hormone status.
It is well known that at present, a high proportion of patients receiving dialysis therapy have relatively low serum PTH levels. In parallel, the observation that CV calcifications are more prevalent in patients undergoing dialysis who have low serum PTH levels than in those with normal or moderately elevated levels, in association with low-turnover bone disease, this condition favors mineral deposition in vascular and other soft tissues instead of bone. Results from several studies, all of them reported an increase in CV mortality risk in patients with low PTH levels.
Nonetheless, consistent evidence associating Compare SHPT with low serum PTH levels which mortality rate is higher in patients undergoing dialysis is still lacking. so, in this prospective, observational clinical trial study. the investigators will observe the mortality and CV incidence rate between SHPT and low serum PTH levels. the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are Less than 300pg/ml and more than the 800pg/ml are chosen to involve in this study. According to PTH levels The patients will be divided into two groups. Both two groups of patients will receive a reasonable treatment according to the suggestions in K/DOQI guidelines. Then, all of the patients will be followed for 24 months to compare the rate of cardiovascular and cerebrovascular events and mortality in each group.
|Study Type :||Observational|
|Estimated Enrollment :||827 participants|
|Official Title:||the Study on Difference Prognostic for Low Parathyroid Hormone Levels and Severe Secondary Hyperparathyroidism in Hemodialysis Patients|
|Actual Study Start Date :||January 1, 2017|
|Estimated Primary Completion Date :||January 1, 2019|
|Estimated Study Completion Date :||January 1, 2019|
- All-cause mortality [ Time Frame: 24 months ]all of the patients will be followed for 24 months to compare the all-cause mortality.
- the rate of cardiovascular and cerebrovascular events. [ Time Frame: 24 months ]all of the patients will be followed for 24 months to compare the rate of cardiovascular and cerebrovascular events.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03194087
|Contact: Zongli Diao, firstname.lastname@example.org|
|Beijing Friendship hospital||Recruiting|
|Beijing, Beijing, China, 100050|
|Contact: Wenhu Liu, Doctor +86-01-63139144 email@example.com|
|Principal Investigator: Wenhu Liu, Doctor|
|Study Chair:||WenHu Liu, doctor||Beijing Friendship Hospital|